Next Generation Sequencing

NeoGenomics Pharma Services provides numerous applications and platforms for next-generation sequencing (NGS).

NeoGenomics is one of the early adopters of NGS and has built up flexible and high throughput capability with sequencing platforms such as Illumina HiSeq, MiSeq, NextSeq, and NovaSeq as well as Thermo Fisher Ion Torrent PGM Dx and Ion GeneStudio S5. Our services are optimized for accuracy, reproducibility, sample adaptability, and rapid turnaround times with cost-effective pricing. 

Whole Genome Sequencing (WGS)

Neogenomics Pharma Services offer robust, state-of-the-art whole genome sequencing (WGS) services for researchers interested in obtaining raw data for their own analysis or accompanied with a standard data analysis package. Whole genome sequencing provides a powerful tool for both de novo sequencing and re-sequencing.

  • Services include extraction, library prep, sequencing, alignment, and QC check
  • Single base-pair resolution
  • De novo sequencing and genome-wide mutation characterization
  • Population evolution and phylogenetic studies
  • Disease research, drug discovery and development, and personalized medicine

Whole Exome Sequencing (WES)

Whole exome sequencing (WES) is a next-generation sequencing (NGS) application which generates genomic information for all protein-coding genes across the human genome, providing an unbiased view of the exome. Our CLIA-validated WES services for various specimens are designed for research studies, clinical trials, and clinical diagnostics.

  • Services include pathology review, extraction, library prep, sequencing, alignment, somatic variant calling, and QC check
  • Targeted, deep sequencing of protein-coding regions and UTRs to uncover low frequency SNPs and structural variants
  • Increased sequencing efficiency – Focus on the full throughput of NGS on the regions that contain ~85% of the known disease-causing mutations
  • Multiple capture technologies – Customized assistance to help you select the most efficient exome capture technology

RNA Sequencing (RNA-seq) 

Being a non-hypothesis driven approach, RNA sequencing (RNA-seq) has become a versatile and powerful tool for unbiased characterization of the underlying biology and deepening our understanding of biological processes. It provides unprecedented sensitivity and accuracy for analyzing gene expression and has opened new doors for research by using applications such as whole transcriptome sequencing, rRNA depleted total RNA sequencing, and target capture RNA sequencing.

  • Comprehensive Genomic Information – Gene expression, SNPs, or transcribed mutations, deletions, splice variations, novel transcripts and rearrangements, non-coding and miRNAs
  • Quantitative and precise measurements of RNA molecules at single-nucleotide resolution
  • Large dynamic range allows broad detection of expressed genes
  • Bioinformatics support – fine-tune RNA-seq data output based on project requirements
  • Application to any species, no matter whether reference genome is available

Comprehensive Tumor Molecular Profiling

Targeted region sequencing is an effective approach for investigating selected region(s) of interest by next generation sequencing. We employ state-of-the-art sequencing instruments to help you obtain full genomic information of the selected targets in a cost-effective manner, which can greatly increase both the breadth and depth of your tumor genomics research.

  • High depth (500-1000X, or higher), allowing identification of rare variants
  • Identification of variants at low allele frequencies (down to 3-5%)
  • Smaller data set for bioinformatics analysis
  • Much lower cost for testing a large number of samples
  • Option for standard data analysis package or tailored bioinformatics services for custom solutions and reportables
  • Option for medical/clinical reporting with the ability to customize biomarker reportables for clinical trials
Tumor Profiling Panel Description Gene Panel
Lymphoid 133 Panel Lymphoid 133 gene NGS panel is a laboratory-developed NGS assay. It is intended as an aid in the diagnosis and subclassification of lymphoid neoplasms as well as to identify potential therapies based on the patient's unique molecular drivers. View Gene Panel
Comprehensive Cancer 275 Panel This comprehensive panel includes 275 cancer-relevant genes such as oncogenes, tumor suppressor genes, genes for adhesion, angiogenesis, apoptosis, cell cycle, DNA damage and repair, epigenetics, etc. Validated for a variety of myeloid disorders such as AML, CML, CMML, and MPN, etc. View Gene Panel
Discovery 322 Panel This is a gene-specific primer-based target enrichment panel to enrich targeted genes and construct libraries for NGS. It is designed for 322 most commonly mutated genes in cancers and genes involved in cancer development and progression. Validated for several solid tumor indications such as lung, breast, colon, etc. View Gene Panel



NeoGenomics’ Houston (TX) center of excellence achieves ERIC requirements for certification of Immunoglobulin (IG) mutation testing in CLL samples

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients